누낭염 시장 : 치료, 적응증, 최종사용자 - 세계 예측(2024-2032년)

Global Dacryocystitis Market will record over 5.3% CAGR between 2024 and 2032, catapulted by increasing awareness & diagnosis of the condition, and a rising geriatric population susceptible to eye infections. Innovations such as sophisticated diagnostic tools and minimally invasive surgical techniques have revolutionized treatment approaches, leading to more accurate diagnoses and effective therapies. These technological advancements cut patient recovery time and improve treatment outcomes. Quoting an instance, in May 2023, Bausch + Lomb and Novaliq announced FDA approval of MIEBO(TM) (perfluorohexyloctane ophthalmic solution) for treating dry eye disease. MIEBO is the first FDA-approved eye drop targeting tear evaporation, based on successful results from pivotal Phase 3 trials.

Enhanced imaging technologies, such as high-resolution endoscopy, allow for better visualization of the lacrimal sac and duct systems, facilitating precise interventions for dacryocystitis. Additionally, the development of advanced therapeutic procedures contributes to augmenting efficiency and patient safety, ushering the market growth.

The overall dacryocystitis market is segmented based on treatment, indication, end user, and region.

The medication segment will exhibit a robust CAGR through 2032, because of increasing awareness and diagnosis rates. Improved healthcare access is leading to more patients seeking treatment, spurring the need for effective medication options. Advancements in medical research are resulting in the development of new drug formulations and therapies. The growing prevalence of chronic conditions and an aging population lead to higher prevalence of dacryocystitis. As patients and healthcare providers seek innovative solutions for managing dacryocystitis, the demand for medications will increase.

The acute dacryocystitis segment will achieve a significant market share by 2032, owing to the higher incidence of rapid-onset symptoms. Acute dacryocystitis, characterized by sudden inflammation and infection of the lacrimal sac, requires prompt medical attention. Factors such as an upsurge in bacterial infections and environmental triggers leads to increased cases. Additionally, improved diagnostic capabilities have led to more cases being identified early. Increased patient awareness and proactive healthcare practices drive demand for effective management solutions, ensuring rapid relief from acute symptoms and reducing potential complications.

Europe dacryocystitis market will show a strong CAGR from 2024 to 2032, due to rising awareness and early diagnosis of the condition. The public health initiatives and educational campaigns are leading to more individuals seeking timely treatment. Europe's advanced healthcare infrastructure facilitates access to specialized care, amplifying demand. The region's aging population, which is more susceptible to eye infections, is boosting the need for effective dacryocystitis management solutions. These factors collectively contribute to a positive market outlook.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic and congenital dacryocystitis
    • 3.2.1.2 Growing awareness towards advanced ophthalmic treatment options
    • 3.2.1.3 Increasing aging population
    • 3.2.1.4 Availability of advanced diagnostic techniques to timely diagnose dacryocystitis
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Presence of stringent regulations
    • 3.2.2.2 High risk of side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Surgery
• 5.3 Medication
  • 5.3.1 Antibiotics
  • 5.3.2 Other medications

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chronic dacryocystitis
• 6.3 Acute dacryocystitis
• 6.4 Congenital dacryocystitis

Chapter 7 Market Estimates and Forecast, By Distribution channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Institutional sales
• 7.3 Retail sales

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc. (Allergan)
• 9.2 Alcon Inc.
• 9.3 Aurolab
• 9.4 Bausch Health Companies Inc.
• 9.5 Bayer AG
• 9.6 BVM Medical Limited
• 9.7 F. Hoffmann-La Roche Ltd (Genentech, Inc.)
• 9.8 FCI Ophthalmics
• 9.9 Gunther Weiss Scientific Glassblowing Co., Inc.
• 9.10 Heart Medical Europe BV
• 9.11 Kaneka Corporation
• 9.12 Merck & Co., Inc.
• 9.13 Novartis AG
• 9.14 Pfizer Inc.
• 9.15 Regeneron Pharmaceuticals Inc.